Search Results - "UGES, D"

Refine Results
  1. 1

    Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations by Encalada Ventura, M A, van Wanrooy, M J P, Span, L F R, Rodgers, M G G, van den Heuvel, E R, Uges, D R A, van der Werf, T S, Kosterink, J G W, Alffenaar, J W C

    Published in Antimicrobial agents and chemotherapy (01-05-2016)
    “…Voriconazole (VCZ) exhibits great inter- and intrapatient variability. The latter variation cannot exclusively be explained by concomitant medications, liver…”
    Get full text
    Journal Article
  2. 2

    Determination of moxifloxacin in dried blood spots using LC–MS/MS and the impact of the hematocrit and blood volume by Vu, D.H., Koster, R.A., Alffenaar, J.W.C., Brouwers, J.R.B.J., Uges, D.R.A.

    “…Moxifloxacin (MFX) is a potential oral agent use in the treatment of multidrug-resistance tuberculosis (MDR-TB). Due to variability in pharmacokinetics and in…”
    Get full text
    Journal Article
  3. 3

    Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Linezolid in Patients with Multidrug-Resistant Tuberculosis by VU, D. H, BOLHUIS, M. S, KOSTER, R. A, GREIJDANUS, B, DE LANGE, W. C. M, ALTENA, R. Van, BROUWERS, J. R. B. J, UGES, D. R. A, ALFFENAAR, J. W. C

    Published in Antimicrobial Agents and Chemotherapy (01-11-2012)
    “…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
    Get full text
    Journal Article
  4. 4

    Dried blood spots: a new tool for tuberculosis treatment optimization by Vu, D H, Alffenaar, J W C, Edelbroek, P M, Brouwers, J R B J, Uges, D R A

    Published in Current pharmaceutical design (01-09-2011)
    “…Tuberculosis (TB) is a high-burden infectious disease, especially in low and middle-income countries. The efforts to eliminate this disease are challenged by…”
    Get more information
    Journal Article
  5. 5

    Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors by Boer, H., Proost, J.H., Nuver, J., Bunskoek, S., Gietema, J.Q., Geubels, B.M., Altena, R., Zwart, N., Oosting, S.F., Vonk, J.M., Lefrandt, J.D., Uges, D.R.A., Meijer, C., de Vries, E.G.E., Gietema, J.A.

    Published in Annals of oncology (01-11-2015)
    “…The success of cisplatin-based (Platinol, Bristol-Myers Squibb Company, New York, NY, USA) chemotherapy for testicular cancer comes at the price of long-term…”
    Get full text
    Journal Article
  6. 6

    Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MS by Alffenaar, J.W.C., Wessels, A.M.A., van Hateren, K., Greijdanus, B., Kosterink, J.G.W., Uges, D.R.A.

    “…Fungal infections occur in immunocompromised patients. Azole antifungal agents are used for the prophylaxis and treatment of these infections. The interest in…”
    Get full text
    Journal Article
  7. 7

    Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience by PRANGER, A. D, VAN ALTENA, R, AARNOUTSE, R. E, VAN SOOLINGEN, D, UGES, D. R. A, KOSTERINK, J. G. W, VAN DER WERF, T. S, ALFFENAAR, J. W. C

    Published in The European respiratory journal (01-10-2011)
    “…Moxifloxacin (MFX) is a powerful second-line anti-tuberculosis (TB) agent, but the optimal dose has not yet been established and long-term safety data are…”
    Get full text
    Journal Article
  8. 8

    Clinical Validation of the Analysis of Linezolid and Clarithromycin in Oral Fluid of Patients with Multidrug-Resistant Tuberculosis by BOLHUIS, M. S, VAN ALTENA, R, VAN HATEREN, K, DE LANGE, W. C. M, GREIJDANUS, B, UGES, D. R. A, KOSTERINK, J. G. W, VAN DER WERF, T. S, ALFFENAAR, J. W. C

    Published in Antimicrobial Agents and Chemotherapy (01-08-2013)
    “…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
    Get full text
    Journal Article
  9. 9

    Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC–MS/MS by Vu, D.H., Koster, R.A., Bolhuis, M.S., Greijdanus, B., Altena, R.V., Nguyen, D.H., Brouwers, J.R.B.J., Uges, D.R.A., Alffenaar, J.W.C

    Published in Talanta (Oxford) (01-04-2014)
    “…Rifampicin (RIF) and clarithromycin (CLR) are common drugs for the treatment of infections like Mycobacterium tuberculosis and Mycobacterium ulcerans…”
    Get full text
    Journal Article
  10. 10

    Five year results of an international proficiency testing programme for measurement of antifungal drug concentrations by Lempers, V J C, Alffenaar, J W C, Touw, D J, Burger, D M, Uges, D R A, Aarnoutse, R E, Brüggemann, R J M

    Published in Journal of antimicrobial chemotherapy (01-11-2014)
    “…Since 2007 the Dutch Association for Quality Assessment in Therapeutic Drug Monitoring (KKGT) has organized an international interlaboratory proficiency…”
    Get full text
    Journal Article
  11. 11

    Pharmacokinetics of Rifampin and Clarithromycin in Patients Treated for Mycobacterium ulcerans Infection by Alffenaar, J W C, Nienhuis, W A, de Velde, F, Zuur, A T, Wessels, A M A, Almeida, D, Grosset, J, Adjei, O, Uges, D R A, van der Werf, T S

    Published in Antimicrobial Agents and Chemotherapy (01-09-2010)
    “…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
    Get full text
    Journal Article
  12. 12

    Reconsideration of sample pH adjustment in bioanalytical liquid–liquid extraction of ionisable compounds by Hendriks, G., Uges, D.R.A., Franke, J.P.

    “…Liquid–liquid extraction (LLE) is widely used as a simple and robust sample preparation technique in bioanalytical sample preparation. When extracting…”
    Get full text
    Journal Article
  13. 13

    Troubleshooting carry-over of LC–MS/MS method for rifampicin, clarithromycin and metabolites in human plasma by Vu, D.H., Koster, R.A., Wessels, A.M.A., Greijdanus, B., Alffenaar, J.W.C., Uges, D.R.A.

    “…► “Carry-over” of rifampicin and 25 desacetyl rifampicin was originated in the column. ► Replacing the polar end-capped phase column excluded the “carry-over”…”
    Get full text
    Journal Article
  14. 14

    Surface roughness, porosity and wettability of gentamicin-loaded bone cements and their antibiotic release by VAN DE BELT, H, NEUT, D, UGES, D. R. A, SCHENK, W, VAN HORN, J. R, VAN DER MEI, H. C, BUSSCHER, H. J

    Published in Biomaterials (01-10-2000)
    “…In this study, the release of gentamicin as a function of time was measured for six different gentamicin-loaded bone cements and related with the surface…”
    Get full text
    Journal Article
  15. 15

    Electrochemical and surface characterization of a nickel–titanium alloy by Wever, D.J., Veldhuizen, A.G., de Vries, J., Busscher, H.J., Uges, D.R.A., van Horn, J.R.

    Published in Biomaterials (01-04-1998)
    “…For clinical implantation purposes of shape memory metals the nearly equiatomic nickel–titanium (NiTi) alloy is generally used. In this study, the corrosion…”
    Get full text
    Journal Article
  16. 16
  17. 17

    Intravenous Voriconazole after Toxic Oral Administration by ALFFENAAR, J. W. C, VAN ASSEN, S, DE MONCHY, J. G. R, UGES, D. R. A, KOSTERINK, J. G. W, VAN DER WERF, T. S

    Published in Antimicrobial Agents and Chemotherapy (01-06-2010)
    “…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
    Get full text
    Journal Article
  18. 18

    Genetic factors influencing Pyrimidine-antagonist chemotherapy by Maring, J G, Groen, H J M, Wachters, F M, Uges, D R A, de Vries, E G E

    Published in The pharmacogenomics journal (01-08-2005)
    “…Pyrimidine antagonists, for example, 5-fluorouracil (5-FU), cytarabine (ara-C) and gemcitabine (dFdC), are widely used in chemotherapy regimes for colorectal,…”
    Get full text
    Journal Article
  19. 19

    pH adjustment of human blood plasma prior to bioanalytical sample preparation by Hendriks, G., Uges, D.R.A., Franke, J.P.

    “…pH adjustment in bioanalytical sample preparation concerning ionisable compounds is one of the most common sample treatments. This is often done by mixing an…”
    Get full text
    Journal Article
  20. 20

    Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer by Gietema, JA, Meinardi, MT, Messerschmidt, J, Gelevert, T, Alt, F, Uges, DRA, Th Sleijfer, D

    Published in The Lancet (British edition) (25-03-2000)
    “…We have shown in patients cured from metastatic testicular cancer that up to 20 years after administration of cisplatincontaining chemotherapy, circulating…”
    Get full text
    Journal Article